Arcutis Biotherapeutics, Inc. ARQT Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s restricted cash?
- Arcutis Biotherapeutics, Inc. (ARQT) reported restricted cash of $308K in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s restricted cash changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s restricted cash decreased by 50.1% year-over-year, from $617K to $308K.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s restricted cash has grown at a -27.5% compound annual growth rate (CAGR), from $1.54M to $308K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.